{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "CitationSubset": ["IM"], "OtherAbstract": [], "KeywordList": [["Advanced metastatic melanoma", "Anti-PD-1 immunotherapy", "Immune checkpoint inhibitors", "Nivolumab", "Pembrolizumab"]], "GeneralNote": [], "OtherID": [], "InvestigatorList": [], "PMID": "31760100", "DateCompleted": {"Year": "2020", "Month": "01", "Day": "13"}, "DateRevised": {"Year": "2020", "Month": "01", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "11", "Day": "21"}], "Language": ["eng"], "ELocationID": ["10.1016/j.lfs.2019.117093", "S0024-3205(19)31020-3"], "Journal": {"ISSN": "1879-0631", "JournalIssue": {"Volume": "240", "PubDate": {"Year": "2020", "Month": "Jan", "Day": "01"}}, "Title": "Life sciences", "ISOAbbreviation": "Life Sci"}, "ArticleTitle": "Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges.", "Pagination": {"StartPage": "117093", "MedlinePgn": "117093"}, "Abstract": {"AbstractText": ["Immunotherapy with immune checkpoint inhibitors, such as anti-PD-1 drugs, is an area in increasing development for its efficacy and advantages in the treatment of advanced metastatic melanoma. In fact, immunotherapy has been the target of several and recent studies in different types of cancer, namely in melanoma, a globally growing threat. Contributing to the increasing incidence of this cancer is climate change, particularly global warming of the past century, which has increased the tendency to spend more time outdoors and, consequently, exposure to sunlight and ultraviolet radiation. Among the most relevant risk factors for melanoma is the increase in ultraviolet radiation due to ozone layer depletion, one of the main factors responsible for the incidence of new cases. Anti-PD-1 agents like Nivolumab and Pembrolizumab allow a more effective treatment, enhancing the duration of the responses to therapy and prolonging the survival of the patient. However, recent studies about safety and tolerability have stated that, although these drugs present less adverse effects and toxicity, they may lead to specific autoimmune-mediated adverse events. Overall, immunotherapy with anti-PD-1 agents represents a highly promising area in the treatment of some types of cancer such as melanoma."], "CopyrightInformation": "Copyright \u00a9 2019 Elsevier Inc. All rights reserved."}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "LAQV, REQUIMTE, Laboratory of Bromatology and Pharmacognosy, Faculty of Pharmacy, University of Coimbra, P\u00f3lo das Ci\u00eancias da Sa\u00fade, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal."}], "Identifier": [], "LastName": "Moreira", "ForeName": "Rita S", "Initials": "RS"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, P\u00f3lo das Ci\u00eancias da Sa\u00fade, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; CIBIT/ICNAS - Coimbra Institute for Biomedical Imaging and Translational Research, P\u00f3lo das Ci\u00eancias da Sa\u00fade, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal. Electronic address: joana.bicker@gmail.com."}], "Identifier": [], "LastName": "Bicker", "ForeName": "Joana", "Initials": "J"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Regina Elena San Gallicano IRCCS di Roma, 00144 Roma, Italy. Electronic address: felice.musicco@ifo.gov.it."}], "Identifier": [], "LastName": "Musicco", "ForeName": "Felice", "Initials": "F"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Regina Elena San Gallicano IRCCS di Roma, 00144 Roma, Italy. Electronic address: agnese.persichetti@ifo.gov.it."}], "Identifier": [], "LastName": "Persichetti", "ForeName": "Agnese", "Initials": "A"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "LAQV, REQUIMTE, Laboratory of Bromatology and Pharmacognosy, Faculty of Pharmacy, University of Coimbra, P\u00f3lo das Ci\u00eancias da Sa\u00fade, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal. Electronic address: andrepereira@ff.uc.pt."}], "Identifier": [], "LastName": "Pereira", "ForeName": "Andr\u00e9 M P T", "Initials": "AMPT"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Life Sci", "NlmUniqueID": "0375521", "ISSNLinking": "0024-3205"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antibodies, Monoclonal, Humanized"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents, Immunological"}, {"RegistryNumber": "0", "NameOfSubstance": "B7-H1 Antigen"}, {"RegistryNumber": "31YO63LBSN", "NameOfSubstance": "Nivolumab"}, {"RegistryNumber": "DPT0O3T46P", "NameOfSubstance": "pembrolizumab"}], "CommentsCorrectionsList": [{"RefSource": "Life Sci. 2020 Mar 15;245:117433. doi: 10.1016/j.lfs.2020.117433", "PMID": "32115223"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antibodies, Monoclonal, Humanized"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antineoplastic Agents, Immunological"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "B7-H1 Antigen"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["methods"], "DescriptorName": "Immunotherapy"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Melanoma"}, {"QualifierName": [], "DescriptorName": "Neoplasm Metastasis"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Nivolumab"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2019", "Month": "10", "Day": "2"}, {"Year": "2019", "Month": "11", "Day": "18"}, {"Year": "2019", "Month": "11", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "1", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "11", "Day": "25", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["31760100", "10.1016/j.lfs.2019.117093", "S0024-3205(19)31020-3"]}}]}